ClinicalTrials.gg
TerminatedNCT00139074Updated Jan 28, 2013

Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients

A Phase 4 interventional study of Quetiapine fumarate and sodium valproate in Bipolar Disorder, sponsored by AstraZeneca. Terminated at 7 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-28.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Why this study was terminated
terminated due to very low recruitment rate (27 June 2006)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing Valproic Acid in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Valproic Acid · Bipolar Disorder.

Enrollment
37th of 41
17 · median 58
Started
2005
with 4 others
Phase 4
20 of 41
none open now
Registered
7th of 41
by date
Lead sponsor
2 of 41
AstraZeneca

Among the 41 studies testing Valproic Acid in Bipolar Disorder, this one is the 37th largest by enrollment, is one of 5 that started in 2005, is one of 20 in phase 4, and was the 7th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 41 studies testing Valproic Acid in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About Valproic Acid

Valproic Acid: first FDA approval 1978 (DEPAKENE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing Valproic Acid in Bipolar Disorder as a file.
02

Study summary

The primary purpose is to investigate whether the addition of sodium valproate will be superior to treatment with quetiapine (Seroquel) given as monotherapy for an additional 14 days in non-responding patients after a 14 day initial treatment period with quetiapine.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Bipolar I Disorder (DSM-IV 296.01, DSM-IV 296.4, DSM-IV 296.61)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suffering from a manic or mixed episode.

Exclusion criteria

Exclusion Criteria:

  • Patients who have not provided personal ,
  • Known intolerance, or lack of antimanic response to sodium valproate or quetiapine fumarate,
  • Involuntary admittance/detainment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Active comparator
    1

    quetiapine fumarate monotherapy

    Drug: Quetiapine fumarate

  • Experimental
    2

    Quetiapine + sodium valproate

    Drug: Quetiapine fumarate · Drug: sodium valproate

Interventions

06

What researchers measure

Primary outcomes

  1. The number of responders in the two treatment groups (quetiapine + sodium valproate placebo/quetiapine + sodium valproate)

    Time frame: after 2 weeks treatment

07

Study locations

7 sites
  • Research Site
    Esbjerg, Denmark
  • Research Site
    Frederikssund, Denmark
  • Research Site
    Haderslev, Denmark
  • Research Site
    Hellerup, Denmark
  • Research Site
    Kobenhavn, Denmark
  • Research Site
    Kolding, Denmark
  • Researcg Site
    Svendborg, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Jul 2005
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Jan 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00139074
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 31, 2005
Start date
Jul 2005
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Jan 28, 2013

Study contacts

Dr. Rasmus Wenzer Licht
principal investigator · AstraZeneca
AstraZeneca Seroquel Medical Science Director, MD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion